ATyr Short Term Investments vs Total Stockholder Equity Analysis

ATYR Stock

3.44 0.15 4.56%

ATyr Pharma, financial indicator trend analysis is way more than just evaluating aTyr Pharma, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether aTyr Pharma, is a good investment. Please check the relationship between ATyr Pharma, Short Term Investments and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in aTyr Pharma,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in ATyr Stock, please use our How to Invest in ATyr Pharma, guide.

Short Term Investments vs Total Stockholder Equity

Short Term Investments vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of aTyr Pharma, Short Term Investments account and Total Stockholder Equity. At this time, the significance of the direction appears to have totally related.

The correlation between ATyr Pharma,'s Short Term Investments and Total Stockholder Equity is 1.0. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of aTyr Pharma,, assuming nothing else is changed. The correlation between historical values of ATyr Pharma,'s Short Term Investments and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of aTyr Pharma, are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Short Term Investments i.e., ATyr Pharma,'s Short Term Investments and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Short Term Investments

Short Term Investments is an item under the current assets section of ATyr Pharma, balance sheet. It contains any investments aTyr Pharma, undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that aTyr Pharma, can easily liquidate in the marketplace.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from ATyr Pharma,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into aTyr Pharma, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in aTyr Pharma,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in ATyr Stock, please use our How to Invest in ATyr Pharma, guide.At this time, ATyr Pharma,'s Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 11/28/2024, Enterprise Value is likely to grow to about 89.6 M, while Selling General Administrative is likely to drop slightly above 12.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	32.7M	55.1M	55.3M	46.2M
Cost Of Revenue	1.3M	1.7M	2.7M	4.6M

Total Operating Expenses Cost Of Revenue

ATyr Pharma, fundamental ratios Correlations

	Other Current Assets	Short Long Term Debt	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Other Current Assets		-0.35	0.88	0.4	0.49	0.46	0.93	0.38	0.89	-0.59	0.33	-0.76	0.39	-0.75	0.91	0.25	0.56	0.95	0.43	0.4	0.77	0.42	0.93	0.35	0.92	0.62
Short Long Term Debt	-0.35		-0.6	-0.6	-0.62	-0.63	-0.55	-0.59	-0.28	0.88	-0.6	-0.11	-0.59	0.8	-0.58	-0.16	-0.68	-0.51	-0.85	-0.6	-0.72	-0.61	-0.55	-0.6	-0.57	-0.68
Total Assets	0.88	-0.6		0.74	0.81	0.79	0.98	0.72	0.88	-0.86	0.68	-0.44	0.73	-0.94	0.98	0.35	0.88	0.97	0.75	0.74	0.98	0.76	0.98	0.69	0.99	0.9
Short Long Term Debt Total	0.4	-0.6	0.74		0.99	1.0	0.61	1.0	0.61	-0.87	0.99	0.14	1.0	-0.72	0.63	0.61	0.94	0.56	0.92	1.0	0.85	1.0	0.61	0.99	0.66	0.89
Other Current Liab	0.49	-0.62	0.81	0.99		1.0	0.69	0.99	0.69	-0.9	0.98	0.04	0.99	-0.77	0.7	0.63	0.95	0.64	0.93	0.99	0.9	1.0	0.69	0.98	0.73	0.91
Total Current Liabilities	0.46	-0.63	0.79	1.0	1.0		0.67	0.99	0.66	-0.89	0.99	0.07	1.0	-0.76	0.68	0.62	0.95	0.62	0.94	1.0	0.89	1.0	0.67	0.99	0.71	0.91
Total Stockholder Equity	0.93	-0.55	0.98	0.61	0.69	0.67		0.59	0.88	-0.78	0.54	-0.55	0.6	-0.92	1.0	0.25	0.78	1.0	0.64	0.61	0.93	0.63	1.0	0.55	1.0	0.83
Property Plant And Equipment Net	0.38	-0.59	0.72	1.0	0.99	0.99	0.59		0.6	-0.86	1.0	0.15	1.0	-0.69	0.61	0.64	0.93	0.53	0.92	1.0	0.83	1.0	0.59	0.99	0.64	0.87
Net Debt	0.89	-0.28	0.88	0.61	0.69	0.66	0.88	0.6		-0.65	0.57	-0.69	0.62	-0.67	0.84	0.62	0.65	0.87	0.56	0.61	0.81	0.63	0.88	0.6	0.88	0.65
Retained Earnings	-0.59	0.88	-0.86	-0.87	-0.9	-0.89	-0.78	-0.86	-0.65		-0.85	0.08	-0.86	0.91	-0.8	-0.46	-0.91	-0.74	-0.97	-0.87	-0.94	-0.88	-0.78	-0.85	-0.81	-0.89
Accounts Payable	0.33	-0.6	0.68	0.99	0.98	0.99	0.54	1.0	0.57	-0.85		0.19	1.0	-0.66	0.56	0.66	0.9	0.49	0.92	0.99	0.8	0.99	0.54	1.0	0.59	0.84
Cash	-0.76	-0.11	-0.44	0.14	0.04	0.07	-0.55	0.15	-0.69	0.08	0.19		0.12	0.22	-0.49	-0.22	0.04	-0.6	0.1	0.14	-0.26	0.11	-0.55	0.14	-0.51	-0.01
Non Current Assets Total	0.39	-0.59	0.73	1.0	0.99	1.0	0.6	1.0	0.62	-0.86	1.0	0.12		-0.7	0.62	0.65	0.92	0.55	0.92	1.0	0.84	1.0	0.6	1.0	0.65	0.87
Non Currrent Assets Other	-0.75	0.8	-0.94	-0.72	-0.77	-0.76	-0.92	-0.69	-0.67	0.91	-0.66	0.22	-0.7		-0.94	-0.15	-0.89	-0.9	-0.81	-0.72	-0.95	-0.73	-0.92	-0.65	-0.93	-0.93
Cash And Short Term Investments	0.91	-0.58	0.98	0.63	0.7	0.68	1.0	0.61	0.84	-0.8	0.56	-0.49	0.62	-0.94		0.2	0.82	0.99	0.66	0.63	0.94	0.65	1.0	0.56	1.0	0.86
Net Receivables	0.25	-0.16	0.35	0.61	0.63	0.62	0.25	0.64	0.62	-0.46	0.66	-0.22	0.65	-0.15	0.2		0.37	0.22	0.55	0.61	0.41	0.62	0.25	0.7	0.29	0.27
Common Stock Shares Outstanding	0.56	-0.68	0.88	0.94	0.95	0.95	0.78	0.93	0.65	-0.91	0.9	0.04	0.92	-0.89	0.82	0.37		0.74	0.9	0.94	0.94	0.94	0.78	0.89	0.82	0.99
Short Term Investments	0.95	-0.51	0.97	0.56	0.64	0.62	1.0	0.53	0.87	-0.74	0.49	-0.6	0.55	-0.9	0.99	0.22	0.74		0.59	0.56	0.9	0.58	1.0	0.5	0.99	0.8
Non Current Liabilities Total	0.43	-0.85	0.75	0.92	0.93	0.94	0.64	0.92	0.56	-0.97	0.92	0.1	0.92	-0.81	0.66	0.55	0.9	0.59		0.92	0.88	0.93	0.64	0.93	0.69	0.86
Capital Lease Obligations	0.4	-0.6	0.74	1.0	0.99	1.0	0.61	1.0	0.61	-0.87	0.99	0.14	1.0	-0.72	0.63	0.61	0.94	0.56	0.92		0.85	1.0	0.61	0.99	0.66	0.89
Other Stockholder Equity	0.77	-0.72	0.98	0.85	0.9	0.89	0.93	0.83	0.81	-0.94	0.8	-0.26	0.84	-0.95	0.94	0.41	0.94	0.9	0.88	0.85		0.86	0.93	0.81	0.95	0.95
Total Liab	0.42	-0.61	0.76	1.0	1.0	1.0	0.63	1.0	0.63	-0.88	0.99	0.11	1.0	-0.73	0.65	0.62	0.94	0.58	0.93	1.0	0.86		0.63	0.99	0.68	0.9
Net Invested Capital	0.93	-0.55	0.98	0.61	0.69	0.67	1.0	0.59	0.88	-0.78	0.54	-0.55	0.6	-0.92	1.0	0.25	0.78	1.0	0.64	0.61	0.93	0.63		0.55	1.0	0.83
Property Plant And Equipment Gross	0.35	-0.6	0.69	0.99	0.98	0.99	0.55	0.99	0.6	-0.85	1.0	0.14	1.0	-0.65	0.56	0.7	0.89	0.5	0.93	0.99	0.81	0.99	0.55		0.61	0.83
Total Current Assets	0.92	-0.57	0.99	0.66	0.73	0.71	1.0	0.64	0.88	-0.81	0.59	-0.51	0.65	-0.93	1.0	0.29	0.82	0.99	0.69	0.66	0.95	0.68	1.0	0.61		0.86
Capital Stock	0.62	-0.68	0.9	0.89	0.91	0.91	0.83	0.87	0.65	-0.89	0.84	-0.01	0.87	-0.93	0.86	0.27	0.99	0.8	0.86	0.89	0.95	0.9	0.83	0.83	0.86

Click cells to compare fundamentals

ATyr Pharma, Account Relationship Matchups

Pair Trading with ATyr Pharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.

Moving together with ATyr Stock

0.78

BMY

Bristol Myers Squibb Aggressive Push

Pair Corr

Moving against ATyr Stock

0.87	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.78	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.77	FDMT	4D Molecular Therapeutics	Pair Corr
0.74	PEPG	PepGen	Pair Corr
0.62	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.

The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ATyr Stock Analysis

When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC